key: cord-0970755-ohykfmss
authors: Matsuo, Rumi; Matsumoto, Naomi; Kadowaki, Tomoka; Mitsuhashi, Toshiharu; Takao, Soshi; Yorifuji, Takashi
title: Effect of mRNA Vaccines in Preventing COVID-19 Severe Pneumonia Among COVID-19 Patients in Japan
date: 2022-03-05
journal: J Epidemiol
DOI: 10.2188/jea.je20210487
sha: ef7735696225c31122dcaba3581c8056cbc4fbb1
doc_id: 970755
cord_uid: ohykfmss

nan

Following descriptive analyses, we conducted Poisson regression with robust error variance to examine the associations between vaccination status and the primary and secondary outcomes. We estimated risk ratios (RRs) and their 95% confidence intervals (CIs) adjusting for age category, sex, smoking status, and comorbidities based on the results of a previous study. 4 The study was approved by the Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Ethical Committee (No. K2110-020), which waived requirement for informed consent because this was a retrospective study and complete anonymity was ensured.

More than half of study participants were aged 20 to 39 years (60.62%; n = 1,632) and men (56.35%; n = 1,517). Compared with unvaccinated patients, the adjusted RRs for COVID-19 severe pneumonia were 0.53 (95% CI, 0.30-0.94) for partially vaccinated and 0.25 (95% CI, 0.09-0.67) for fully vaccinated patients (Table 1) . Although the results of stratified analyses were unstable, the preventive effects of vaccination were observed even in older patients and in patients with comorbidities.

We demonstrated the effect of mRNA vaccines (BNT162b2 and mRNA-1273) in protecting against COVID-19 severe pneumonia and pneumonia among patients with COVID-19 in Japan. Our results are consistent with those of previous studies of healthy individuals in Western countries. 5 We provide further evidence that mRNA vaccines can decrease the risk of severe outcomes by 70% among patients with COVID-19, consistent with a study from England. 6 A strength of our study was that we used data from a Public Health Center and all cases occurring in a whole city were included. A limitation of our study was that information was collected by the patients, so there is a possibility of misclassification. Although we adjusted for several risk factors for severity, which would be related to the vaccination status in the statistical analyses, there is a possibility of residual confounding. Moreover, vaccination coverage is still limited, especially for patients <50 years old, so we could not evaluate the effects among that age category.

We thank Hiroaki Matsuoka, Tomoe Kodama, Saori Irie, and Yoko Oka for valuable support in collecting data. We thank Edanz (https:==jp.edanz.com=ac) for editing a draft of this manuscript.

Authors' contributions: RM analyzed the data and wrote the first draft; NM, TK, TM, ST and TY contributed to the interpretation of the data and revised the manuscript. All authors read and approved the final manuscript.

Conflicts of interest: None declared. Source of funding: This study was supported by a grant from Okayama City (no. 7402100053) for COVID-19 research projects.

Data availability: Data cannot be shared for privacy or ethical reasons. mRNA Vaccines and COVID-19 Severe Pneumonia

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. C4591001 Clinical Trial Group

L452R mutant test results. https:==www.pref. okayama.jp=page=724270.html#00-452henikabu-pcr

Clinical management of Patients with COVID-19 (version 5.3). https:==www.mhlw. go.jp=content=000829136.pdf

Risk factors for severity on admission and the disease progression during hospitalisation in a large cohort of patients with COVID-19 in Japan

Coverage and estimated effectiveness of mRNA COVID-19 vaccines among US veterans

Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant. https:==media.tghn.org=articles=Effectiveness_of_COVID-19_ vaccines_against_hospital_admission_with_the_Delta_B